Cargando…

Is idiopathic pulmonary fibrosis a cancer-like disease? Transcriptome analysis to fuel the debate

Despite promising examples of anticancer drugs as potential treatment modalities for IPF, these transcriptome data argue against the general nature of anticancer drugs as anti-IPF drugs http://ow.ly/HjsV30nbcji

Detalles Bibliográficos
Autores principales:	Spek, C. Arnold, Duitman, JanWillem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2019
Materias:	Original Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355975/ https://www.ncbi.nlm.nih.gov/pubmed/30723726 http://dx.doi.org/10.1183/23120541.00157-2018

Ejemplares similares

Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?
por: Duitman, JanWillem, et al.
Publicado: (2019)

PCSK6: The Endogenous PAR-1 Agonist Driving Pulmonary Fibrosis?
por: Spek, C. Arnold, et al.
Publicado: (2023)

Myeloid DNA methyltransferase3b deficiency aggravates pulmonary fibrosis by enhancing profibrotic macrophage activation
por: Qin, Wanhai, et al.
Publicado: (2022)

Plasmin reduces fibronectin deposition by mesangial cells in a protease-activated receptor-1 independent manner
por: Waasdorp, Maaike, et al.
Publicado: (2017)

Protease‐activated receptor‐1 contributes to renal injury and interstitial fibrosis during chronic obstructive nephropathy
por: Waasdorp, Maaike, et al.
Publicado: (2018)

Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner
por: Spek, C. Arnold, et al.
Publicado: (2022)

CCAAT/enhancer binding protein delta (C/EBPδ) deficiency does not affect bleomycin-induced pulmonary fibrosis
por: JanWillem, Duitman, et al.
Publicado: (2018)

Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice
por: Waasdorp, Maaike, et al.
Publicado: (2016)

Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
por: Waasdorp, Maaike, et al.
Publicado: (2018)

Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?
por: Slapak, Etienne J., et al.
Publicado: (2020)

Non-Tumor CCAAT/Enhancer-Binding Protein Delta Potentiates Tumor Cell Extravasation and Pancreatic Cancer Metastasis Formation
por: Duitman, JanWillem, et al.
Publicado: (2021)

CEBPD Potentiates the Macrophage Inflammatory Response but CEBPD Knock-Out Macrophages Fail to Identify CEBPD-Dependent Pro-Inflammatory Transcriptional Programs
por: Spek, C. Arnold, et al.
Publicado: (2021)

C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC
por: Hartl, Leonie, et al.
Publicado: (2023)

Fueling the debate.
Publicado: (1997)

Detrimental role for CCAAT/enhancer binding protein δ in blood-borne brain infection
por: Duitman, JanWillem, et al.
Publicado: (2016)

Fueling the gas debate.
Publicado: (1996)

CCAAT/enhancer-binding protein δ (C/EBPδ) aggravates inflammation and bacterial dissemination during pneumococcal meningitis
por: Serón, Mercedes Valls, et al.
Publicado: (2015)

Possible Alternate Explanation for Cases of Idiopathic Pulmonary Fibrosis
por: Frank, Arthur L.
Publicado: (2022)

C/EBPδ Suppresses Motility-Associated Gene Signatures and Reduces PDAC Cell Migration
por: Hartl, Leonie, et al.
Publicado: (2022)

Pulmonary arterial hypertension preceding idiopathic pulmonary fibrosis in a BMPR2 mutation positive patient
por: Raamsteeboers, Aniek J., et al.
Publicado: (2014)

Potential Delays in Diagnosis of Idiopathic Pulmonary Fibrosis in Medicare Beneficiaries
por: Mooney, Joshua, et al.
Publicado: (2019)

Reply: Possible Alternate Explanation for Cases of Idiopathic Pulmonary Fibrosis
por: Kaul, Bhavika, et al.
Publicado: (2022)

Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis
por: Kraven, Luke M, et al.
Publicado: (2023)

How many patients with idiopathic pulmonary fibrosis are there in Brazil?
por: Baddini-Martinez, José, et al.
Publicado: (2015)

Economic consequences of idiopathic pulmonary fibrosis in Denmark
por: Hilberg, Ole, et al.
Publicado: (2018)

Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis
por: de Brouwer, Bart, et al.
Publicado: (2018)

The Peripheral Blood Transcriptome Identifies the Presence and Extent of Disease in Idiopathic Pulmonary Fibrosis
por: Yang, Ivana V., et al.
Publicado: (2012)

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
por: Maher, Toby M., et al.
Publicado: (2019)

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
por: Costabel, Ulrich, et al.
Publicado: (2019)

Myelodysplastic syndromes and idiopathic pulmonary fibrosis: a dangerous liaison
por: Papiris, Spyros A., et al.
Publicado: (2019)

Monocyte as a prognostic marker in patients with idiopathic pulmonary fibrosis
por: Zhu, Shiping
Publicado: (2021)

Genetic overlap between idiopathic pulmonary fibrosis and COVID−19
por: Allen, Richard J, et al.
Publicado: (2022)

Protease activated receptor-1 regulates macrophage-mediated cellular senescence: a risk for idiopathic pulmonary fibrosis
por: Lin, Cong, et al.
Publicado: (2015)

Transcriptome Classification Reveals Molecular Subgroups in Idiopathic Pulmonary Fibrosis
por: Liu, Yuxia, et al.
Publicado: (2022)

Coronavirus disease 2019 pneumonia may present as an acute exacerbation of idiopathic pulmonary fibrosis
por: Lee, Yong Hoon, et al.
Publicado: (2020)

Comment on “Analysis of Microarray-Identified Genes and MicroRNAs Associated with Idiopathic Pulmonary Fibrosis”
por: Li, Chenyu, et al.
Publicado: (2018)

Idiopathic pulmonary fibrosis: airway volume measurement identifies progressive disease on computed tomography scans
por: McLellan, Thomas, et al.
Publicado: (2020)

Disparities in Rural Populations With Idiopathic Pulmonary Fibrosis
por: DeDent, Alison M., et al.
Publicado: (2022)

Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis
por: Molyneaux, Philip L., et al.
Publicado: (2017)

Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience
por: Mullerpattan, Jai B, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rcrajndjem7o3et87iequk12qo